Success Metrics

Clinical Success Rate
61.5%

Based on 8 completed trials

Completion Rate
62%(8/13)
Active Trials
2(12%)
Results Posted
100%(8 trials)
Terminated
5(29%)

Phase Distribution

Ph phase_4
5
29%
Ph phase_2
6
35%
Ph phase_1
1
6%
Ph phase_3
5
29%

Phase Distribution

1

Early Stage

6

Mid Stage

10

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
1(5.9%)
Phase 2Efficacy & side effects
6(35.3%)
Phase 3Large-scale testing
5(29.4%)
Phase 4Post-market surveillance
5(29.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

61.5%

8 of 13 finished

Non-Completion Rate

38.5%

5 ended early

Currently Active

2

trials recruiting

Total Trials

17

all time

Status Distribution
Active(2)
Completed(8)
Terminated(5)
Other(2)

Detailed Status

Completed8
Terminated5
unknown2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
2
Success Rate
61.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (5.9%)
Phase 26 (35.3%)
Phase 35 (29.4%)
Phase 45 (29.4%)

Trials by Status

unknown212%
recruiting16%
active_not_recruiting16%
terminated529%
completed847%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT03078010Phase 2

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

Active Not Recruiting
NCT06954129Phase 4

A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients

Recruiting
NCT05079620Phase 4

Early Antibiotics After Aspiration in ICU Patients

Terminated
NCT02820987Phase 3

PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock

Completed
NCT04983901Phase 2

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Completed
NCT03485950Phase 2

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

Completed
NCT04816968Phase 1

Antibiotics Continuous Infusion at Home

Unknown
NCT04009772Phase 2

Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section

Unknown
NCT02497781Phase 2

Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)

Completed
NCT00137787Phase 3

Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases

Completed
NCT02872038Phase 4

Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis

Completed
NCT02302092Phase 3

An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections

Terminated
NCT02732327Phase 2

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Terminated
NCT01110408Phase 3

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

Terminated
NCT01110421Phase 3

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

Terminated
NCT00609375Phase 4

Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen

Completed
NCT00358202Phase 4

Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17